Antenatal Corticosteroid Therapy to Prevent Neonatal Respiratory Distress Syndrome.
- Author:
Keun Young LEE
;
Kyung Hee LEE
;
Jung Bae KANG
;
Hong Bae KIM
;
Young Ah LEE
;
Duck Ha KIM
;
Jong Tae PARK
;
Sung Won KANG
- Publication Type:Original Article
- Keywords:
Neonatal respiratory distress syndrome;
Antenatal corticosteroid therapy
- MeSH:
Dexamethasone;
Enterocolitis, Necrotizing;
Female;
Humans;
Incidence;
Pregnancy;
Respiratory Distress Syndrome, Newborn*;
Sepsis
- From:Korean Journal of Perinatology
1997;8(2):178-185
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: Our purpose was to determine the efficacy of maternal corticosteroid therapy in the prevention of neonatal respiratory distress syndrome. STUDY DESIGN: The data in this study was taken from 136 women who participated in prematurity prevention programs at two hospital. Of 136 women who were delivered at 25 to 34 weeks, 68 received dexamethasone and 68 did not. 'I'he frequency and relative risk of adverse outcomes, including repiratory distress syndrome, necrotizing enterocolitis, neonatal sepsis and maternal infection wcre compared by means of univariate techniques. RESULT: When dexamethansone was administered, there was a lower incidence of respiratory distress syndrome at between 30 to 32 weeks gestation (relative risk of treatment group vs control group=0.425, p<0.05) and there was no statistical difference between 24 to 26 weeks (relative risk of treatment group vs control group=0.833, p>0.05). I'here was no statistical difference between 33 weeks to 34 weeks (relative risk of treatment group vs control group=0.782, p>0.05). 'I'here was no statistical significance in the incidence of maternal infection, neonatal sepsis or necrotizing enterocolitis (p=0.808, p=0.698, p=0.559). CONCLUSION: Dexamethasone appears to significantly reduce neonatal respiratory distress syndrome at between 30 and 32 weeks gestation.
